Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Colizzi, Marco
START, NCT06187090: The Supplementation Therapy in Autism and Response to Treatment Study	Recruiting	N/A	20	Europe	Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form	University of Udine	Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Asperger Syndrome, Depressive Symptoms, Anxiety State	11/25	11/26
EARLY, NCT06037993: Endocannabinoid Activity Remodulation for Psychosis Liability in Youth	Recruiting	N/A	20	Europe	Ultra-micronized Palmitoylethanolamide (PEA)	University of Udine, National Research Council (CNR), Institute of Biomolecular Chemistry (ICB), Italy	Clinical High Risk for Psychosis, Ultra High Risk for Psychosis, Attenuated Psychotic Symptoms	11/24	11/25
Bortoletto, Riccardo
START, NCT06187090: The Supplementation Therapy in Autism and Response to Treatment Study	Recruiting	N/A	20	Europe	Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form	University of Udine	Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Asperger Syndrome, Depressive Symptoms, Anxiety State	11/25	11/26
EARLY, NCT06037993: Endocannabinoid Activity Remodulation for Psychosis Liability in Youth	Recruiting	N/A	20	Europe	Ultra-micronized Palmitoylethanolamide (PEA)	University of Udine, National Research Council (CNR), Institute of Biomolecular Chemistry (ICB), Italy	Clinical High Risk for Psychosis, Ultra High Risk for Psychosis, Attenuated Psychotic Symptoms	11/24	11/25